Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC
Business Wire•19/10/2026•08:30 ET
0
Key Highlights
- ➤60,459 advanced NSCLC cases analyzed across 56,969 patients
- ➤AI panel exceeded 80% sensitivity across all 12 biomarkers
- ➤Sensitivity exceeded 90% for several assessed biomarkers
- ➤H&E pre-screening panel remains in development and does not replace established testing
- ➤Study conducted through Tempus-Pfizer collaboration on biomarker testing
Expert Statements
Ezra Cohen, Chief Medical Officer of Oncology at Tempus
“Precision medicine only works when clinicians have the right information at the right time.”
Ezra Cohen, Chief Medical Officer of Oncology at Tempus
“These findings demonstrate the potential for AI to extract meaningful information from a pathology image that is already part of routine care and help clinicians determine what testing may be most important next.”
Ezra Cohen, Chief Medical Officer of Oncology at Tempus
“This builds on our efforts to apply AI to routine diagnostic data to help more patients benefit from precision medicine.”
Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC
Study presented at ESMO evaluated more than 60,000 advanced NSCLC cases and found greater than 80% sensitivity across all 12 biomarkers using routine H&E pathology images
Get started
Create a free account to read the full story.